Michelsen, BrigitteLindström, UlfCodreanu, CatalinCiurea, AdrianZavada, JakubLoft, Anne GittePombo-Suarez, ManuelOnen, FatosKvien, Tore KRotar, ZigaSantos, Maria JoseIannone, FlorenzoHokkanen, Anna-MariGudbjornsson, BjornAskling, JohanIonescu, RuxandraNissen, Michael JPavelka, KarelSanchez-Piedra, CarlosAkar, ServetSexton, JosephTomsic, MatijaSantos, HelenaSebastiani, MarcoÖsterlund, JennyGeirsson, Arni JonMacfarlane, Garyvan der Horst-Bruinsma, IreneGeorgiadis, StylianosBrahe, Cecilie HeegaardØrnbjerg, Lykke MidtbøllHetland, Merete LundØstergaard, Mikkel2020-10-212020-10-212020Michelsen, B, Lindström, U, Codreanu, C, Ciurea, A, Zavada, J, Loft, A G, Pombo-Suarez, M, Onen, F, Kvien, T K, Rotar, Z, Santos, M J, Iannone, F, Hokkanen, A-M, Gudbjornsson, B, Askling, J, Ionescu, R, Nissen, M J, Pavelka, K, Sanchez-Piedra, C, Akar, S, Sexton, J, Tomsic, M, Santos, H, Sebastiani, M, Österlund, J, Geirsson, A J, Macfarlane, G, van der Horst-Bruinsma, I, Georgiadis, S, Brahe, C H, Ørnbjerg, L M, Hetland, M L & Østergaard, M 2020, 'Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment : routine care data from 13 registries in the EuroSpA collaboration', RMD Open, vol. 6, no. 3, e001280. https://doi.org/10.1136/rmdopen-2020-0012802056-5933ORCID: /0000-0003-2322-3314/work/82378990https://hdl.handle.net/2164/15261Acknowledgements Thanks to Novartis Pharma AG and IQVIA for supporting the EuroSpA collaboration. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Contributors The study protocol and analysis plan was drafted by BM, MØ and MLH and revised and approved by all authors. Data analyses were done by BM and draft of the manuscript by BM, MØ, MLH and LØ. All authors have contributed substantially to the acquisition and interpretation of data, revised the manuscript for importantintellectual content and approved the final submitted version. Funding The EuroSpA collaboration was financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. The national registries have received financial support froma range of pharmaceutical companies, including Novartis. These funds are given as unrestricted grants.121117120engDMARDs (biologic)Outcomes researchSpondyloarthritisR MedicineImmunology and AllergyRheumatologyImmunologyRJournal article10.1136/rmdopen-2020-001280http://www.scopus.com/inward/record.url?scp=85091265627&partnerID=8YFLogxK63